Skip to main content

letter

. 1996 Sep 14;313(7058):686. doi: 10.1136/bmj.313.7058.686a

Use of hormone replacement therapy. May depend on whether the menopause is regarded as physiological or pathological.

PMCID: PMC2352004 PMID: 8811767

686

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Colditz G. A., Hankinson S. E., Hunter D. J., Willett W. C., Manson J. E., Stampfer M. J., Hennekens C., Rosner B., Speizer F. E. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589–1593. doi: 10.1056/NEJM199506153322401. [DOI] [PubMed] [Google Scholar]
Hunt K., Vessey M., McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol. 1990 Dec;97(12):1080–1086. doi: 10.1111/j.1471-0528.1990.tb02494.x. [DOI] [PubMed] [Google Scholar]
Paganini-Hill A. Oestrogen replacement therapy and Alzheimer's disease. Br J Obstet Gynaecol. 1996 May;103 (Suppl 13):80–86. [PubMed] [Google Scholar]
Price E. H., Little H. K. Women need to be fully informed about risks of hormone replacement therapy. BMJ. 1996 May 18;312(7041):1301–1301. doi: 10.1136/bmj.312.7041.1301. [DOI] [PMC free article] [PubMed] [Google Scholar]
Stanford J. L., Weiss N. S., Voigt L. F., Daling J. R., Habel L. A., Rossing M. A. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA. 1995 Jul 12;274(2):137–142. [PubMed] [Google Scholar]

ACTIONS

RESOURCES